Knight Total Assets from 2010 to 2026
| GUD Stock | CAD 5.97 0.07 1.19% |
Total Assets | First Reported 2013-09-30 | Previous Quarter 1 B | Current Value 1 B | Quarterly Volatility 284.4 M |
Check Knight Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Knight Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 64.1 M, Interest Expense of 9.2 M or Selling General Administrative of 26.3 M, as well as many indicators such as Price To Sales Ratio of 1.59, Dividend Yield of 0.31 or PTB Ratio of 1.11. Knight financial statements analysis is a perfect complement when working with Knight Therapeutics Valuation or Volatility modules.
Knight | Total Assets |
Evaluating Knight Therapeutics's Total Assets across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Knight Therapeutics's fundamental strength.
Latest Knight Therapeutics' Total Assets Growth Pattern
Below is the plot of the Total Assets of Knight Therapeutics over the last few years. Total assets refers to the total amount of Knight Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Knight Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Knight Therapeutics' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Knight Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 963.8 M | 10 Years Trend |
|
Total Assets |
| Timeline |
Knight Total Assets Regression Statistics
| Arithmetic Mean | 738,511,201 | |
| Geometric Mean | 7,283,028 | |
| Coefficient Of Variation | 61.89 | |
| Mean Deviation | 387,701,886 | |
| Median | 963,797,000 | |
| Standard Deviation | 457,067,838 | |
| Sample Variance | 208911T | |
| Range | 1.3B | |
| R-Value | 0.80 | |
| Mean Square Error | 79126.2T | |
| R-Squared | 0.64 | |
| Significance | 0.0001 | |
| Slope | 72,687,938 | |
| Total Sum of Squares | 3342576.1T |
Knight Total Assets History
About Knight Therapeutics Financial Statements
Knight Therapeutics investors utilize fundamental indicators, such as Total Assets, to predict how Knight Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Assets | 1.1 B | 961.1 M | |
| Intangibles To Total Assets | 0.35 | 0.36 |
Other Information on Investing in Knight Stock
Knight Therapeutics financial ratios help investors to determine whether Knight Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Knight with respect to the benefits of owning Knight Therapeutics security.